GPCR
Structure Therapeutics
$48.69
−$0.43 (−0.88%)Jul 27, 2026
Key metrics
The numbers that frame GPCR today
- Market cap
- $3.46B
- P/E (TTM)
- -20.3
- EV / FCF
- -19.8
- ROIC
- -21.3%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $15.80
- 52wk High
- $94.90
Growth
Revenue and earnings trend for GPCR
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about GPCR
Is Structure Therapeutics a good buy?
Hold. Structure Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Structure Therapeutics is selling at a high price.
What is the market capitalization of GPCR?
Structure Therapeutics's market capitalization is $3.46B.
What is the P/E ratio for GPCR stock?
Structure Therapeutics's current P/E ratio is -20.3.
What is the 52-week high for GPCR stock?
The 52-week high for Structure Therapeutics is $94.90. The current close of $48.69 is 48.7% below that high.
What is the 52-week low for GPCR stock?
The 52-week low for Structure Therapeutics is $15.80. The current close of $48.69 is 208.2% above that low.
Does GPCR stock pay dividends?
Structure Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for GPCR?
Structure Therapeutics's Debt / Equity ratio is 0.